DIA
30.1.2024 10:01:28 CET | Business Wire | Press release
DIA, a global organization of life sciences professionals, will emphasize how collaboration and innovation can support sustainability in healthcare at DIA Europe 2024, to be held March 12-14 at Square Brussels Convention Centre in Brussels.
DIA Europe, the largest and most forward-looking neutral healthcare conference on the continent, is the only event that gives representatives from the European Commission, the European Medicines Agency (EMA), the World Health Organization (WHO), the Heads of Medicines Agencies (HMA), national competent authorities, healthcare professionals, and patient populations the opportunity to come together to shape key policy decisions.
Now in its 36th year, DIA Europe will feature discussions on the environmental footprint of pharmaceuticals and drug development. Panelists will explore optimal sustainability practices with more than 250 guest speakers across 11 rich content tracks that comprise 100-plus sessions, including much-anticipated "DIAmond sessions" and town halls. They will also participate in collaboration hubs, showcases, and workshops designed to drive change and innovative thinking.
"Sustainability is one of the defining challenges in healthcare today," said Ania Mitan, DIA's Senior Vice President and Managing Director, EMEA and India. "No organization can tackle it alone, but through open dialogue, partnership across industry, government, and academia, and listening to the patient's perspective, we can drive real progress. Learning from each other will empower us to develop new approaches that benefit patients, society, and our planet."
Attendees will hear from more than 25 EMA executives, including Emer Cooke, the Executive Director of the EMA and the Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA); Martin Harvey Allchurch, the EMA's Head of International Affairs; and Dr. Peter Arlett, the EMA's Head of Data Analytics and Methods Task Force.
Leda Stott, a Senior Research Fellow at the Innovation and Technology for Development Centre at the Technical University of Madrid and an authority on multi-stakeholder collaboration; Veronique Toully, the Global Head of Sustainability, Corporate Affairs and Risks at UCB; and Dr. Glenn Wells, Chief Partnerships Officer at the Medicines and Healthcare Products Regulatory Agency (MHRA), will deliver a keynote address that examines healthcare's most pressing sustainability challenges.
Other can't-miss sessions include:
— "EU Regulatory Town Hall: The New Pharmaceutical Legislation": Explore how we are increasing availability and access to novel healthcare solutions.
— "Digital Transformation in the EU Regulatory Space": Discuss how Europe is building the foundations for its digital transformation in the regulatory space for the next 10 years.
— "Complexity: Interplay and Interface of Different Legislations": Learn how we can drive medicine research, development, and manufacturing amid an increasingly complicated landscape of EU policies and regulations.
Three new content tracks this year will cover emerging trends in healthcare: Artificial Intelligence, Data Science, and Real-World Evidence; Innovative Therapies, Precision Medicine, and Diagnostics; and International Collaboration and Regional Updates.
DIA is celebrating 60 years of bringing together leading minds to foster innovation, collaboration, and advancement in global healthcare.
At DIA Europe, everyone meets on equal terms. To register to attend as a participant or media member, visit https://www.diaglobal.org/Flagship/DIA-Europe-2024.
About DIA
DIA is a leading global life science membership association that drives collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries.
Learn more at DIAglobal.org, and connect with DIA on LinkedIn, Facebook, X (Twitter), and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130133798/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom